Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma

A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)

Cabozantinib (C) in combination with Nivolumab (N) and Ipilimumab (I) (CaNI) for advanced Renal Cell Carcinoma with Variant Histology (aRCCVH)

Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma

APART – A Phase 2 trial of Axitinib, Palbociclib and Avelumab as Renal Cell Carcinoma Therapy

Maturation of overall survival (OS) in TIVO-3 with long-term follow-up

Interim Analysis of PADRES (Prior Axitinib as a Determinant of Outcome of Renal Surgery NCT03438708) Clinical Trial

SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma

Belzutifan plus lenvatinib versus cabozantinib after anti–PD-1/ PD-L1 treatment in patients with advanced renal cell carcinoma: the randomized, phase 3 LITESPARK-011 study

Phase II Trial of Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma

TiNivo-2: A Phase 3 Study to Compare Tivozanib Plus Nivolumab to Tivozanib Monotherapy in Patients with RCC Who Have Progressed Following ≤2 Lines of Therapy Including an Immune Checkpoint Inhibitor

A Phase 1/2, Open Label Dose- Escalation and Expansion Trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety. PK, PD and clinical activity in patients with advanced ccRCC

Pembrolizumab plus belzutifan as adjuvant treatment of clear cell renal cell carcinoma: phase 3 LITESPARK-022 study